Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229.
Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y et al. Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67: 8839–8846.
Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754–3762.
Reichwagen A, Ziepert M, Kreuz M, Gödtel-Armbrust U, Rixecker T, Poeschel V et al. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics 2015; 16: 361–372.
Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422–1428.
Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 2013; 163: 205–213.
Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D et al. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Res Treat 2014; 147: 557–570.
Hertz DL, Caram MV, Kidwell KM, Thibert JN, Gersch C, Seewald NJ et al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics 2016; 17: 231–240.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat 2015; 152: 67–76.
Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009; 23: 1118–1126.
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol 2014; 89: 639–645.
Megías-Vericat JE, Montesinos P, Herrero MJ, Bosó V, Martínez-Cuadrón D, Poveda JL et al. Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics 2016; 7: 1245–1272, [Epub ahead of print]..
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.
Colovic N, Tomin D, Vidovic A, Suvajdzic N, Jankovic G, Palibrk V et al. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. Biomed Pharmacother 2012; 66: 578–582.
Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006; 8: 691–728.
Schirmer M, Hoffmann M, Kaya E, Tzvetkov M, Brockmoller J. Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenomics J 2008; 8: 297–304.
Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744–1747.
Wyche KE, Wang SS, Griendling KK, Dikalov SI, Austin H, Rao S et al. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004; 43: 1246–1251.
Shimo-Nakanishi Y, Hasebe T, Suzuki A, Mochizuki H, Nomiyama T, Tanaka Y et al. Functional effects of NAD(P)H oxidase p22(phox) C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 2004; 175: 109–115.
Fang S, Wang L, Jia C. Association of p22phox gene C242T polymorphism with coronary artery disease: a meta-analysis. Thromb Res 2010; 125: e197–e201.
Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 2012; 118: 1856–1867.
Hoffman M, Schirmer M, Tzvetkov M, Kreuz M, Ziepert M, Wojnowski L et al. A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res 2010; 70: 2328–2338.
Cascales A, Pastor-Quirante F, Sánchez-Vega B, Luengo-Gil G, Corral J, Ortuño-Pacheco G et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist 2013; 18: 446–453.
Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007; 7: 129–134.
Li X, Shao M, Wang S, Zhao X, Chen H, Qian J et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol 2014; 35: 11159–11170.
Morrison BA, Davis C, Ucisik-Akkaya E, Tevfik Dorak M. MHC associations in childhood leukemia: identification of heterozygote advantage. Hum Immunol 2008; 69: S69 (abstract 180-P).